MedTechDive on the Cedars v Quest court case. September 17, 2019.
https://www.medtechdive.com/news/quest-didnt-steal-cedars-sinai-blood-test-in-trade-secrets-row-jury-says/562909/
Original Complaint 11//2017, 24pp
https://www.documentcloud.org/documents/6407574-CedarsSinaicomplaint2017.html
Quest says no: 09/2019, 31pp
https://assets.documentcloud.org/documents/6407575/Questmemoranduminsupportofjudgmentasamatteroflaw.pdf
Sound bite from MedTechDive:
As to the trade secrets claims, Quest said Cedars-Sinai not only failed to prove it had any ownership interest in the claimed trade secrets but also had failed to prove any of the trade secrets were actually secret. Quest said the information was never actually secret because the hospital had been actively shopping its test to multiple companies at the same time it was in discussions with Quest.
The jury ultimately rejected Cedars-Sinai's trade secret claims.
Quest Diagnostics' senior director of external engagement Dennis Moynihan told MedTech Dive the company was pleased with the verdict.
Meanwhile, Cedars-Sinai is still committed to protecting Pimentel's innovations, Laura Coverson, senior communications specialist at the hospital, told MedTech Dive.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.